Company news
Bridgebio Oncology Therapeutics, Inc. (NASDAQ:BBOT) news
Bridgebio Oncology Therapeutics, Inc. news releases on 6ix. Latest, Sep 8, 2026: BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC…
Press releases & updates
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
September 8, 2026
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 11, 2026
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 12, 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
April 22, 2026
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
April 21, 2026
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
April 20, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 12, 2026
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 18, 2026
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
March 6, 2026
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
March 5, 2026
BBOT to Participate in Upcoming Investor Healthcare Conferences
February 12, 2026
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
January 6, 2026
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 16, 2025
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
December 9, 2025
BBOT to Participate in Upcoming December Investor Healthcare Conferences
November 18, 2025
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
November 11, 2025
BBOT to Participate in the Jefferies Global Healthcare Conference in London
November 3, 2025
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
October 30, 2025
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
October 25, 2025
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 23, 2025
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 12, 2025
BBOT to Participate in Upcoming September Investor Healthcare Conferences
August 20, 2025
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
August 11, 2025
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
February 27, 2025